Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-02-18
2001-10-16
Celsa, Bennett (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S302000, C530S305000, C530S330000
Reexamination Certificate
active
06303578
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to peptides that bind with high affinity and selectivity to the mu (morphine) opiate receptor; pharmaceutical preparations containing an effective amount of the peptides or salts thereof; and methods for providing analgesia, relief from gastrointestinal disorders such as diarrhea, and therapy for drug dependence containing an effective amount of the peptides.
2. Description of Related Art
Many peptides have been found that exhibit opiate-like activity by binding to opiate receptors. Three different types of opiate receptors have been found: delta (&dgr;), kappa (&kgr;) and mu (&mgr;). The major putative function for opiates is their role in alleviating pain. Other areas where opiates are well-suited for use in treatment are conditions relating to gastrointestinal disorders, schizophrenia, obesity, blood pressure, convulsions, and seizures. Although the &dgr; and &kgr; receptors may also mediate analgesia, activation of &mgr; receptors is the primary and most effective means of inducing analgesia, and is the primary mechanism by which morphine acts.
To date, opiates, opioid peptides, and analogs thereof, have demonstrated a limited degree of specificity and selectivity for the receptor or receptors to which they may bind. The less selective and specific an opiate may be, the greater the chance that increased side effects from the administration of the material will be observed. When an opiate activates more than one receptor, the biological response profile for each receptor is affected, thereby potentiating a spectrum of side effects which may or may not be adverse. Such adverse side effects include heaviness of the limbs, flush or pale complexion, clogged nasal and sinus passages, dizziness, and depression. Compounds that activate &kgr; receptors frequently induce dysphoria.
Peptides have been identified in mammalian brain that are considered endogenous agonists for &dgr; (enkephalins) and &kgr; (dynorphins) opiate receptors, but none show clear preference for the &mgr; receptor. Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH
2
) (SEQ ID NO:27) is an endogenous peptide isolated from human (1) and bovine (2) brain with opiate-related activity in the gunna pig ileum (1,2,3) and in tests of analgesia (4,5,6). It is highly selective for &mgr; over &dgr; and &kgr; receptors (>200- and 300-fold), but its &mgr; receptor affinity (Ki=70 nM) is relatively low (7). Numerous analogs have been made, most of which are based on modifications of the naturally occurring enkephalins that prefer the &dgr; opiate receptor, or dynorphins that prefer the &kgr; receptor. In addition, most of these analogs are relatively hydrophilic, limiting their access to the central nervous system.
Because morphine and other compounds with clinical usefulness act primarily at the &mgr; receptor, endogenous peptides with high affinity and selectivity for this site would be of considerable importance. These peptides, and analogs based on such peptides, that have a natural selectivity for the &mgr; receptor would be advantageous for activating the &mgr; receptor. It would also be desirable to synthesize these peptides in a simple, efficient, and economical manner to facilitate the preparation of suitable quantities for toxicological studies and commercial suppliers while retaining the optical integrity of the desired materials.
SUMMARY OF THE INVENTION
This invention relates to certain peptides and linear and cyclic analogs thereof that bind to the mu (morphine) opiate receptor with high affinity, selectivity and potency. These peptides have the general formula Tyr-X
1
-X
2
-X
3
wherein X
1
is Pro, D-Lys or D-Orn; X
2
is Trp, Phe or N-alkyl-Phe wherein alkyl contains 1 to about 6 carbon atoms; and X
3
is Phe, Phe-NH
2
, D-Phe, D-Phe-NH
2
or p-Y-Phe wherein Y is NO
2
, F, Cl or Br. This invention also relates to pharmaceutical preparations containing an effective amount of the peptides or salts thereof, and methods for providing analgesia, relief from gastrointestinal disorders such as diarrhea, and therapy for drug dependence containing an effective amount of the peptides. In preferred embodiments, the peptides of the invention have the formulas represented by:
H-Tyr-Pro-Trp-Phe-NH
2
(SEQ ID NO:1)
H-Tyr-Pro-Phe-Phe-NH
2
(SEQ ID NO:2)
H-Tyr-Pro-Trp-Phe-OH (SEQ ID NO:3)
H-Tyr-Pro-Phe-Phe-OH (SEQ ID NO:4)
H-Tyr-Pro-Trp-D-Phe-NH
2
(SEQ ID NO:5)
H-Tyr-Pro-Phe-D-Phe-NH
2
(SEQ ID NO:6)
H-Tyr-Pro-Trp-pNO
2
-Phe-NH
2
(SEQ ID NO:7)
H-Tyr-Pro-Phe-pNO
2
-Phe-NH
2
(SEQ ID NO:8)
H-Tyr-Pro-N-Me-Phe-Phe-NH
2
(SEQ ID NO:9)
H-Tyr-Pro-N-Et-Phe-Phe-NH
2
(SEQ ID NO:10)
H-Tyr-Pro-N-Me-Phe-D-Phe-NH
2
(SEQ ID NO:11)
H-Tyr-Pro-N-Et-Phe-D-Phe-NH
2
(SEQ ID NO:12)
H-Tyr-c-[D-Lys-Trp-Phe]
H-Tyr-c-[D-Lys-Phe-Phe]
H-Tyr-c-[D-Orn-Trp-Phe]
H-Tyr-c-[D-Orn-Phe-Phe]
H-Tyr-c-[D-Lys-Trp-pNO
2
-Phe]
H-Tyr-c-[D-Lys-Phe-pNO
2
-Phe]
H-Tyr-c-[D-Orn-Trp-pNO
2
-Phe]
H-Tyr-c-[D-Orn-Phe-pNO
2
-Phe]
H-Tyr-c-[D-Lys-N-Me-Phe-Phe]
H-Tyr-c-[D-Orn-N-Me-Phe-Phe]
H-Tyr-c-[D-Lys-N-Et-Phe-Phe]
H-Tyr-c-[D-Orn-N-Et-Phe-Phe]
H-Tyr-c-[D-Lys-N-Me-Phe-D-Phe]
H-Tyr-c-[D-Lys-N-Et-Phe-D-Phe]
The last fourteen peptides listed are cyclic peptides whose linear primary amino acid sequences are given in SEQ ID NO:13 through SEQ ID NO:26.
REFERENCES:
patent: 4350627 (1982-09-01), DeCastiglione et al.
patent: 5312899 (1994-05-01), Schiller
patent: 5455230 (1995-10-01), Schiller
patent: 95/22557 (1995-08-01), None
patent: WO95/22557 (1995-08-01), None
patent: WO96/40208 (1996-12-01), None
patent: WO97/03210 (1997-01-01), None
patent: WO97/07130 (1997-02-01), None
Sakaguchi et al., Bull. Chem. Soc. Jpn. vol. 65, No. 4 pp. 1052-1056, Apr. 1992.*
Schiller et al. PNAS USA vol. 89, pp. 11871-11875, Dec. 1992.*
Dayhoff et al., Atlas of Protein Sequence and Structure vol. 5, pp. 88-99, 1972.*
Schiller, et al.,Proc. Natl. Acad. Sci. USA.89:11871-11875 (1992).
Schiller, et al.,J. Med. Chem.32:698-703 (1989).
Dooley, et al.,Peptide Res.8:124-137 (1995).
Zadina, et al.,Life Sci.55:PL 461-466 (1994).
Zadina, et al.,Peptides. 15:1567-1569 (1994).
Makarov et al.,Cell88:657-666 (1997).
Zadina et al.,Nature38613:499-502 (1997).
Sakaguchi et al.,Bull. Chem. Soc. Jpn.65:1052-1056 (1992).
Schiller et al.,Advances in the Biosciences75:85-88, (1989).
Hackler Laszlo
Kastin Abba J.
Zadina James E.
Administrators of the Tulane Educational Fund
Celsa Bennett
Howrey Simon Arnold & White , LLP
LandOfFree
Mu-opiate receptor peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mu-opiate receptor peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mu-opiate receptor peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2595121